Medicine and Dentistry
Malignant Neoplasm
100%
Advanced Cancer
83%
Advance Care Planning
78%
Symptomatic Treatment
75%
Systematic Review
63%
Hepatic Encephalopathy
50%
Placebo
43%
Meta-Analysis
36%
Care Pathway
36%
Drug Therapy
35%
Symptom
30%
Clinical Trial
29%
Hazard Ratio
26%
Diseases
25%
Chronic Obstructive Pulmonary Disease
24%
Oncologist
24%
Oncology
23%
Spectroscopy
21%
Brain Disease
21%
Decision Making
20%
Dying
20%
Shared Decision Making
20%
Supportive Care
19%
Butylscopolamine
18%
Quality of Life
18%
Life Expectancy
18%
Observational Study
17%
Clinician
16%
Liver Disease
16%
Patient Referral
15%
Attitude
14%
Restlessness
14%
Controlled Clinical Trial
14%
Cohort Analysis
13%
Oral Mucositis
12%
Thrombosis
12%
Prospective Cohort Study
12%
Glutamic Acid
12%
Informed Consent
12%
Visual Evoked Potential
12%
Neuro-Oncology
12%
Reactive Attachment Disorder
12%
Venous Thromboembolism
12%
Clinical Prediction Model
12%
Idiopathic Pulmonary Fibrosis
12%
Anticoagulant Therapy
12%
Volunteer
12%
Randomized Clinical Trial
12%
Hyperammonemia
12%
Evoked Potential
12%
Nursing and Health Professions
Malignant Neoplasm
93%
Advanced Cancer
67%
Symptom
58%
Advance Care Planning
55%
Health Care Personnel
52%
Systematic Review
50%
Self Care
49%
Drug Therapy
47%
Disease
34%
Quality of Life
33%
Placebo
30%
Oncologist
28%
Life Expectancy
28%
Hepatic Encephalopathy
24%
Palliative Therapy
21%
Cancer Center
20%
Shared Decision-Making
19%
Dying
17%
Palliative Care
16%
Patient Referral
15%
Cohort Analysis
15%
Self-Efficacy
14%
Fluid Intake
14%
Liver Disease
13%
Home Care
13%
Psychosocial Disorder
12%
Participatory Action Research
12%
Fibrosing Alveolitis
12%
Obstructive Lung Disease
12%
Volunteer
12%
Prospective Cohort Study
12%
Nurse Practitioner
12%
Health Status
12%
Area under the Curve
12%
Medical Service
12%
Flumazenil
12%
Deprescribing
12%
Hazard Ratio
12%
Confidence Interval
12%
Meta Analysis
12%
Spectroscopy
9%
Restlessness
9%
General Practitioner
7%
Dyspnea
6%
Scopolamine Butyl Bromide
6%
Predictive Value
6%
Patient Decision Making
6%
Nursing Home
6%
Deprescription
6%
Healthcare System
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
56%
Placebo
36%
Advanced Cancer
34%
Life Expectancy
32%
Randomized Controlled Trial
28%
Pharmacokinetics
27%
Hepatic Encephalopathy
25%
Clinical Trial
24%
Duragesic
24%
Disease
24%
Scopolamine Butyl Bromide
20%
Symptom
20%
Dying
20%
Random Effects Model
20%
Comorbidity
16%
Chemotherapy
15%
Opiate
13%
Neoplasm
13%
Cancer Pain
13%
Controlled Clinical Trial
12%
Observational Study
12%
Chronic Obstructive Lung Disease
12%
Hyperammonemia
12%
Glutamic Acid
12%
Thrombosis
12%
Acute Liver Failure
12%
Medulloblastoma
12%
Oxycodone
12%
Head and Neck Cancer
12%
Liver Disease
12%
Anticoagulant Agent
12%
Venous Thromboembolism
12%
Randomized Clinical Trial
12%
Xerostomia
8%
Scopolamine
6%
Deterioration
6%
Patient Recruitment
6%
Skin Metastasis
6%
Lung Cancer
6%
Cholinergic Receptor Blocking Agent
6%
Mucosa Inflammation
6%
Serum Albumin
6%
Cognitive Defect
6%
Cohort Study
5%
Liver Failure
5%